The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Use of a Long-acting Inhaled β 2 -Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease
Abstract
Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages. This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. Patients were stratified on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were randomized within each stratum. Bronchodilator response was measured over 12 h four times during the treatment period. Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchodilatory effect with no evidence of bronchodilator tolerance. Both active treatments were well tolerated. Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those "unresponsive" to albuterol. The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
A measure of quality of life for clinical trials in chronic lung disease
Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987) · Thorax · doi:10.1136/thx.42.10.773 · Cited by 1,721
Siafakas, N., Vermeire, P., Pride, N., Paoletti, P., Gibson, J., Howard, P., Yernault, J., Decramer, M., Higenbottam, T., Postma, D., et al. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081398 · Cited by 1,592
Ries, A. L., Kaplan, R. M., Limberg, T. M., & Prewitt, L. M. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-11-199506010-00003 · Cited by 903
Prognosis in Chronic Obstructive Pulmonary Disease 1– 3
Anthonisen, N. R., Wright, E. C., Hodgkin, J. E., & IPPB Trial Group (1986) · American Review of Respiratory Disease · doi:10.1164/arrd.1986.133.1.14 · Cited by 777
Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Mahler, D. A., Donohue, J. F., Barbee, R. A., Goldman, M. D., Gross, N. J., Wisniewski, M. E., Yancey, S. W., Zakes, B. A., Rickard, K. A., & Anderson, W. H. (1999) · Chest · doi:10.1378/chest.115.4.957 · Cited by 520
Self-citationQuality of life changes in COPD patients treated with salmeterol.
Jones, P. W., & Bosh, T. K. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.4.9105068 · Cited by 494
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
Boyd, G., Morice, A., Pounsford, J., Siebert, M., Peslis, N., & Crawford, C. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10040815 · Cited by 269
Descriptors of Breathlessness in Cardiorespiratory Diseases
Mahler, D. A., Harver, A., Lentine, T., Scott, J. A., Beck, K., & Schwartzstein, R. M. (1996) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.154.5.8912748 · Cited by 227
Management of Chronic Obstructive Pulmonary Disease
Desforges, J. F., Ferguson, G. T., & Cherniack, R. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281408 · Cited by 189
Cited by
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
Self-citationImproved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Vincken, W., van Noord, J. A., Greefhorst, A. P. M., Bantje, T. A., Kesten, S., Korducki, L., & Cornelissen, P. J. G. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00238702 · Cited by 736
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Calverley, P. M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027003 · Cited by 730
Metadata
- Authors
- RENNARD, S. I., ANDERSON, W., ZuWALLACK, R., BROUGHTON, J., BAILEY, W., FRIEDMAN, M., WISNIEWSKI, M., & RICKARD, K.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04-01
- Volume
- 163
- Issue
- 5
- Pages
- 1087-1092
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2079777289
- Cited by
- 265
- References
- 18
- FWCI
- 24.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of a Long-acting Inhaled β 2 -Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease. https://app.cochat.ai/papers/10.1164/ajrccm.163.5.9903053
- The paper
- RENNARD, S. I., ANDERSON, W., ZuWALLACK, R., BROUGHTON, J., BAILEY, W., FRIEDMAN, M., WISNIEWSKI, M., & RICKARD, K. (2001). Use of a Long-acting Inhaled β 2 -Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.163.5.9903053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.